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ABSTRACT 
 
One of the most common neurological diseases in women of childbearing age is epilepsy, 
affecting approximately 0.8 percent of the women. An increased risk for both fetal and maternal 
complications, has been reported in women with epilepsy due to epilepsy itself, epilepsy related co-
morbidities and antiepileptic drugs. Some of the frequent concerns are reproductive problems, 
pregnancy complications, congenital malformations and developmental problems in the offspring.  
The purpose of this study was to evaluate the fertility and reproductive health in women with 
active epilepsy living in the Kuopio University Hospital area. The study was also extended to evaluate 
the pregnancy outcome of these women and to the assessment of the cognitive and neurological 
performance of the children exposed to valproate and carbamazepine monotherapy during pregnancy.  
We found no difference between women with epilepsy and control women in their reproductive 
health and also the overall rate of women having children was the same, if we exclude the infertility 
caused by a higher proportion of severe co-morbid factors, which differentiate the women with active 
epilepsy from the general population. We followed the pregnant women throughout the pregnancy 
with a pre-decided protocol. The course of pregnancy was uncomplicated in the majority of the 
women with epilepsy. Congenital malformations were observed in 4.8 % of the live-births in women 
with epilepsy and the rate of small-for-date infants as well as the rate of admissions to a neonatal 
intensive care unit, were higher in the infants of the women with epilepsy. Women using valproate for 
epilepsy had a lower intelligence quotient than women using carbamazepine or women without 
antiepileptic drugs and also their level of education was lower, reflecting perhaps the nature of the 
epilepsies responding specifically to valproate. Children exposed to valproate had also lower mean 
intelligence scores, though the difference did not reach statistical significance. They also scored lower 
values in the neuropsychological tests and had received more educational support than children 
exposed to carbamazepine or children without drug exposure. In 62 % of the children exposed to 
valproate, one or more minor dysmorphic features were observed compared to 15% in other children. 
Children with carbamazepine exposure did not differ from controls.  
In conclusion, women with active epilepsy represent a particularly challenging population for 
neurologists and other health care professionals. However, in our population with the pre-decided 
protocol used for the follow-up of pregnancies and well controlled epilepsy, the majority of the 
women with epilepsy have uncomplicated pregnancies. The risk for congenital malformations is 
nearly two-fold in the offspring of women with epilepsy exposed to antiepileptic drugs compared with 
the results of the national malformation registry. The cognitive outcome of children exposed to 
carbamazepine does not differ from controls, which is in line with previous reports. Our findings 
suggest that valproate may have a negative impact on neurocognitive development of the exposed 
offspring, though many confounding factors, including the type of epilepsy and level of schooling of 
the mother, may explain some of this result.  
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Maternal Exposure; Pregnancy; Pregnancy Complications; Pregnancy Outcome; Pregnant Women; 
Prenatal Exposure Delayed Effects; Risk; Uterus/drug effects; Valproic Acid/adverse effects 
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1. INTRODUCTION 
 
Epilepsy is a common neurological disorder, affecting approximately 0.5-1.0 percent of the 
population. It is characterized by recurrent epileptic seizures caused by abnormal excessive or 
synchronous neuronal activity in the brain. The incidence of epilepsy is highest in children 
and in elderly people. Epilepsy is not a specific disease or a single syndrome but rather a 
broad category of symptom complexes arising from disordered brain functions that 
themselves may be secondary to a variety of pathological processes. Recurrent epileptic 
seizures are a cause of severe morbidity and even mortality. In addition to social restrictions, 
seizures may cause injuries and even lead to death. Also, recurrent seizures may have a 
negative effect on a patient’s cognitive abilities. Therefore the active and effective treatment 
of epilepsy is important. Freedom from seizures is the ultimate goal in treating patients with 
epilepsy. 
 
In the majority of patients, epilepsy is well controlled with antiepileptic drugs (AEDs). Two 
thirds of the patients achieve seizure freedom with current antiepileptic medication. However, 
up to 30% of all epilepsy patients develop intractable epilepsy. The goal of the AED treatment is 
to achieve seizure control without causing any adverse effects to the patient. Nowadays over 
20 different AEDs are available and an individualized treatment for every patient should be 
used. Some of intractable epilepsy patients can be also helped by epilepsy surgery. 
 
Women of reproductive age with epilepsy represent a unique group of epilepsy patients due to 
the challenges of epilepsy treatment. Some of the aspects which need to be taken into 
consideration are the effects of AEDs on the female endocrine system, the impact of 
pregnancy on seizure control, the reported maternal and fetal complications and the risk not 
only of epilepsy but also of AED treatment to the developing child and also the long-term 
neurodevelopment of the offspring. 
 
The present study was conducted to provide an overview of the women with epilepsy in 
Kuopio University Hospital area. This study addresses the issue of fertility and hormonal 
factors in women with epilepsy as well as pregnancy complications and the pregnancy 
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outcome. We also studied the long-term effect of AEDs on neurodevelopment in those 
school-aged children who had been exposed to AEDs in utero. 
 17
 
2. REVIEW OF THE LITERATURE 
 
2.1. Epilepsy - definition 
 
According to definitions proposed by the International League Against Epilepsy (ILAE) and 
the International Bureau for Epilepsy (IBE), an epileptic seizure is a transient occurrence of 
signs and/or symptoms due to abnormal excessive or synchronous neuronal activity in the 
brain (Fisher et al. 2005). Epilepsy is a disorder of the brain characterized by an enduring 
predisposition to generate epileptic seizures and by the neurobiologic, cognitive, 
psychological, and social consequences of this condition. The definition of epilepsy requires 
the occurrence of at least one epileptic seizure. Epilepsy is not a specific disease or a single 
syndrome but rather a broad category of symptom complexes arising from disordered brain 
functions that themselves may be secondary to a variety of pathologic processes.  
 
2.2. Epidemiology – prevalence, incidence and aetiology 
 
In the Nordic countries, the prevalence rates of epilepsy vary between 3.6-5.3/1000 in 
children and 5.5-6.3/1000 in adults (Keränen et al. 1989; Forsgren 1992 and 2004, Eriksson 
and Koivikko 1997). Similar results have been reported in other developed countries (Hauser 
et al. 1991). In the less developed countries, the reported prevalence rates have a higher 
variation; in the reports from South and Central America, the prevalence rates tend to be 
higher than those found in the developed countries (Forsgren 2004).   
 
It is still debatable whether epilepsy is more common in men than in women (Forsgren 2004). 
Keränen et al. (1989) and Forsgren (1992) found that the prevalence of epilepsy among men 
was slightly higher than in women. However, the opposite information is also available 
(Hauser et al. 1991). Overall, epilepsy is the most common serious neurological disorder 
affecting approximately 0.5 to 1.0 percent of the population with a slightly higher prevalence 
observed in men (Keränen et al. 1989; Forsgren 1992).  
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The annual incidence rates of epilepsy vary around 50/100 000 according to the studies from 
Sweden and United States (Hauser et al. 1993; Forsgren et al. 1996). In different age-groups, 
the incidence is highest in young children and in the elderly and lowest during young 
adulthood (Hauser et al. 1993; Forsgren et al. 1996; Sillanpää et al. 2006). In recent years, the 
incidence of epilepsy in young children has declined and correspondingly, an increase has 
been observed in the elderly (Forsgren 2004; Sillanpää et al. 2006). Incidence rates have also 
been reported to be higher in men than in women (Keränen et al. 1989; Hauser et al. 1993). 
 
The cause of epilepsy is unknown in the majority of patients (Forsgren 1992; Hauser et al. 
1993). The most common identified aetiology for epilepsy is stroke, accounting for 
approximately 11 % of epilepsy cases (Forsgren 1992; Hauser et al. 1993). Other common 
causes are head trauma 5-7 %, tumour 4-5 % and infection 2-3 %. Neurological deficits 
coexistent with epilepsy have been observed in 7-8% of patients with epilepsy (Forsgren 
1992; Hauser et al. 1993). These epilepsies with a known cause are said to be ‘remote 
symptomatic epilepsies’. It is evident that the more extensive the investigation, the more 
likely it is that etiological factors will be identified. Brain magnetic resonance imaging (MRI) 
identifies a high rate of abnormal findings in hospital based surveys (Li et al. 1995). However, 
no population-based epidemiological study with modern neuroimaging has been reported. 
Therefore, it is likely that the true incidence of symptomatic epilepsies is higher than that 
reported in previous studies, and that MRI will have an important impact on the diagnosis of 
previously undetectable structural abnormalities such as cortical dysplasias underlying 
epilepsy. 
 
2.3. Classification of epilepsies 
  
Epilepsy (or epileptic syndrome) affects all age-groups, has different type of aetiologies and 
manifestations. Therefore epilepsies can be subdivided into groups of characteristic clinical 
features related to e.g. family history of epilepsy, age at the onset of seizures, seizure type and 
associated neurological symptoms and signs. The epileptic syndromes can be divided into 
localization-related (or focal) and generalized epilepsies. According to this aetiology, these 
can be further categorized into idiopathic, symptomatic and probably symptomatic epilepsies. 
Idiopathic epilepsies are presumed to be genetic in origin, symptomatic epilepsies have 
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usually a known cause and probably symptomatic epilepsies are presumed to be symptomatic, 
even though no aetiology has been identified (Engel 2001; Dodson 2004).   
 
Epileptic seizures are classified into two categories; partial seizures with or without secondary 
generalization in which the seizure originates from a focal region and generalized seizures, in 
which the epileptiform activity is present in both hemispheres at the onset of the seizure. The 
International League Against Epilepsy (ILAE) updates the classification of seizure types and 
epileptic syndromes according to the current knowledge (Engel 2001). 
 
2.4. The impact of epilepsy for an individual 
 
Epilepsy is a common, serious neurological disorder. It is described as a disorder of the 
anatomical and functional neuronal network of the brain and is characterised by an enduring 
predisposition to generate epileptic seizures. These seizures can vary in severity e.g. from 
mild subjective symptoms without any impairment of consciousness to automatisms with 
impaired consciousness and on to generalized tonic-clonic seizures with total loss of 
consciousness. Seizures, since they are the most prominent feature of epilepsy, have a serious 
impact on quality of life. 
 
For the individual patient with epilepsy, epileptic seizures are not only socially restricting, but 
they also increase the risk of morbidity and mortality. Accidents and injuries have been 
reported more often in epileptic patients than in the general population (Tomson et al. 2004d). 
These injuries can take many forms e.g. fractures, burns, head traumas and drowning. In a 
recent review by Tomson (2004d) some of the injuries were related more commonly to 
recurrent seizures, especially to generalized tonic-clonic seizures.  
 
An increased risk of unexpected death in patients with epilepsy has been reported in many 
studies (Olafsson et al. 1998c; Lindsten et al. 2000; Mohanraj et al. 2006). Standardised 
mortality ratios (SMR, the difference between observed and expected deaths) are found to be 
2-3 times higher in patients with epilepsy compared to the general population (Lindsten et al. 
2000; Duncan et al. 2006; Mohanraj et al. 2006). In the population-based study by Lindsten et 
al. (2000), an increased mortality rate was observed both in men and in women with epilepsy 
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and it was associated with both partial and generalized seizures. During a 30-year follow-up 
period, the overall survivorship of patients with epilepsy was decreased compared with the 
general population and the SMR was especially high in patients with remote symptomatic 
epilepsy (Olafsson et al. 1998c). In the recent study of patients with newly diagnosed epilepsy 
reported by Mohanraj et al. (2006), the SMR for all patients was 1.42 and for patients not 
responding to treatment 2.54 whereas it was normal, i.e 0.95, for those patients who achieved 
remission emphasizing the importance of seizure control on mortality.  
 
The excess mortality may be due to the underlying aetiology leading to epilepsy, but an 
estimated proportion of 20% is thought to be due to epilepsy itself (Forsgren 2004). These 
epilepsy related deaths are most commonly associated with epileptic seizures e.g. status 
epilepticus and sudden unexpected death in epilepsy (SUDEP). SUDEP, where an otherwise 
healthy person with epilepsy dies unexpectedly with no cause found at autopsy, is the most 
important group of epilepsy related deaths (Nashef and Langan 2004; Tomson et al. 2004d). 
In patients with chronic epilepsy, the rate of SUDEP is higher than in patients with newly 
diagnosed epilepsy (Mohanraj et al. 2006). The increased risk of SUDEP is associated with 
high seizure frequency, early-onset epilepsy and concomitant use of multiple AEDs according 
to the study of Nilsson et al. (1999). 
 
Status epilepticus (SE) is a neurological emergency, in which the epileptic seizure and 
epileptiform activity in the brain persists for over 30 minutes. Convulsive SE is extremely 
harmful to the patient and a recent survey from the United Kingdom (UK) reported that 
mortality during the first SE can be as high as 16% (Rossetti et al. 2006).  
 
The possible effect of epilepsy on the cognitive abilities of the patient has also been 
addressed. People with epilepsy as a group show impaired intellectual performance compared 
with healthy subjects matched for age and education (Perrine and Kiolbasa 1999). Most of the 
studies of cognitive functioning in epilepsy are of patients with chronic epilepsy, but also 
newly diagnosed epilepsy patients have been shown to perform more poorly than control 
subjects in a number of cognitive tasks (Kälviäinen et al. 1992; Prevey et al. 1998; Pulliainen 
et al. 2000; Äikiä et al. 2001). A retrospective analysis of patients with epilepsy, who had 
undergone two evaluations of cognition over a time span of more than 10 years, was reported 
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by Thompson and Duncan (2005). A clear, cognitive decline was seen between the two 
evaluations, and this was associated with a high seizure frequency and the duration of 
epilepsy (Thompson and Duncan 2005).  
 
In addition to epilepsy, many patients have another coexisting disease or disability which may 
have on additional impact on the individual and to the treatment of epilepsy (Jalava and 
Sillanpää 1996; Forsgren 2004; Gaitatzis et al. 2004). These co-morbidity rates are higher in 
patients with epilepsy than in the general population. The observed proportions of 
accompanying conditions in Swedish population are illustrated in Figure 1. Results from the 
Finnish populations of childhood-onset epilepsy as well as from the study of the United 
Kingdom have reported similar results (Jalava and Sillanpää 1996; Eriksson and Koivikko 
1997; Gaitatzis et al. 2004). 
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Figure 1. Results of the Swedish population-based prevalence study of adult epilepsy and 
coexisting disabilities (according to Forsgren 1992). 
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2.5. Antiepileptic drug treatment 
 
The need for effective AED treatment is evident due to the detrimental effects of the epileptic 
seizures and their impact on the individual patient. The recent review of epilepsy-related 
injuries and mortality by Tomson et al. (2004d), concluded that effective treatment of 
epilepsy appears to decrease the injuries and mortality related to epilepsy, which further 
emphasizes the importance of effective epilepsy treatment. Also patients with epilepsy report 
seizure-freedom as one of the most important factors affecting their quality of life (Birbeck et 
al. 2002). 
 
The first AED (potassium bromide) was introduced in 1857 and since that time the treatment 
of epilepsy as well as knowledge of the effects of AEDs have advanced significantly. 
Nowadays over 20 different AEDs are available. Two of the most commonly used AEDs are 
carbamazepine (CBZ) for partial epilepsies and valproate (VPA) for generalized epilepsies, 
which are described in detail in Table 1 below. The aim of the AED treatment is to achieve 
optimal seizure control without eliciting any adverse effects to the patient (Duncan et al. 
2006). According to the current findings, seizure remission can be achieved in approximately 
two thirds of all patients. However, up to 30% of all epilepsy patients develop intractable 
epilepsy (Hauser and Hesdorffer 2001). Despite optimal treatment, these patients continue to 
experience seizures or other symptoms of epileptic syndrome, restricting their ability to lead a 
full life (Hauser and Hesdorffer 2001). Due to the different underlying aetiologies for epilepsy 
and individual variations of the patients, an individualised approach to the treatment of 
epilepsy is recommended (Duncan et al. 2006). Women with epilepsy represent one unique 
group of epilepsy patients whose treatment is challenging since so many aspects need to be 
considered.  
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Table 1. Comparison between the characteristics of carbamazepine and valproate  
 
 Carbamazepine Valproate 
Mechanisms of action Action on neuronal sodium- 
channel conductance 
Action also on monoamine, 
acetylcholine and NMDA 
receptors 
 
Uncertain but may affect GABA 
glutaminergic activity, calcium 
conductance and potassium 
conductance 
Primary indications First-line or adjunct therapy in 
partial and generalized seizures 
(excluding absence and 
myoclonus). Also in Lennox-
Gastaut syndrome and 
childhood epilepsy syndromes 
First-line or adjunct therapy in 
generalized seizures (including 
myoclonus and absence) and 
also in partial seizures, Lennox-
Gastaut syndrome and drug of 
first choice in the syndrome of 
primary generalized epilepsy. 
Also for childhood epilepsy 
syndromes and febrile seizures. 
 
Route of elimination Hepatic metabolism Hepatic metabolism 
 
Maintenance dosages in 
adults (mg/day) 
400-1600 (maximum 2400) 500-2500 
Drug interactions Accelerates hepatic metabolism, 
has many interactions with 
antiepileptic and other drugs 
Number of complex interactions 
with antiepileptic and other 
drugs  
 
Some reported side-effects Drowsiness, fatigue, dizziness, 
ataxia, diplopia, blurring of 
vision, sedation, headache, rash 
and other skin reactions, 
leucopenia, gastrointestinal 
disturbances,  hepatic 
disturbances, endocrine effects 
Weight gain, thinning or loss of 
hair, polycystic ovarian 
syndrome, nausea, vomiting, 
endocrine effects, drowsiness, 
tremor, weakness, 
thrombocytopenia  
Comments First choice drug in tonic-clonic 
and partial seizures in adults and 
children 
Drug of choice in primary 
generalized epilepsy and useful 
in a variety of other epilepsies 
 
 
(Modified from Shorvon S. In: Shorvon S, Perucca E, Fish D, Dodson E , Eds. The Treatment 
of Epilepsy. Oxford:Blackwell Publishing, 2004). 
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2.6. Epilepsy and female reproductive health 
 
It has been estimated that 0.5 % of the childbearing population suffer from epilepsy and 
therefore it is one of the major neurological concerns also to be taken into consideration in 
fertile-aged women (Richmond et al. 2004). Many studies suggest that the fertility in women 
with epilepsy is decreased compared to the general population (Dansky et al. 1980; Webber et 
al. 1986; Artama et al. 2004). In the United States, in women with epilepsy the live birth rate 
was 0.85 of that expected during a 40-year period of time (Webber et al. 1986). The birth rate 
was lowest in the 1940’s and has increased decade by decade so that by the 1970’s no 
reduction was noted (Webber et al. 1986). In the United Kingdom, the fertility rate was found 
by Wallace et al. (1998) to be 33% lower in women with epilepsy compared to controls.  
 
However, in a population-based study from Iceland, no reduction was noted in the fertility of 
women with epilepsy compared with controls (Olafsson et al. 1998b). In that study, 30% of 
women with epilepsy did not have children compared to 25% in the general population and 
only patients with remote symptomatic epilepsy and a severe co-morbidity (e.g. cerebral palsy 
or mental retardation) were childless more often than controls (odds ratio 22) (Olafsson et al. 
1998b). In the study of Dansky et al. (1980), 58% of women with epilepsy had at least one 
pregnancy and 85% of married women had children, but the marriage rate was reduced in 
women with epilepsy compared to unaffected women. Schupf et al. (1996) reported that 
fertility was reduced in patients with epilepsy after the onset of epilepsy but not before its 
appearance. Jalava et al. (1997) reported that women with epilepsy may be disadvantaged in 
terms of marrying but when they are married, their fertility or pregnancies do not differ from 
controls according to a population-based follow-up study of patients with childhood-onset 
epilepsy.  
 
A higher frequency of menstrual disturbances (e.g. anovulatory cycles, irregular menstrual 
cycles) have been reported in women with epilepsy than in unaffected women (Cummings et 
al. 1995; Svalheim et al. 2003; Herzog 2006) and this has been thought to be one of the most 
important factors explaining their reduced fertility. These changes have been associated with 
epilepsy itself and to the use of AEDs. In the retrospective cohort study of Svalheim et al. 
(2003), menstrual disturbances were associated with frequent seizures but not with the 
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epilepsy type. The association of epilepsy type and menstrual disturbances was studied by 
Cummings et al. (1995). They reported that 35.5 % of women with temporal-lobe epilepsy 
(TLE) had anovulatory cycles but this disturbance was not found in any of the women with 
primary generalized epilepsy (PGE). Irregular menstrual cycles and anovulation may also 
occur in association with polycystic ovarian syndrome (PCOS). In some studies, PCOS has, in 
addition to AEDs, been associated with epilepsy itself (Herzog 2006). 
 
Of the individual AEDs, especially VPA has been associated with a high frequency of 
menstrual disturbances (Isojärvi et al. 1993 and 1996; Svalheim et al. 2003). Several 
mechanisms have been proposed e.g. changes in sex hormone levels and a higher prevalence 
of polycystic ovaries (PCO) and hyperandrogenism in women using VPA for epilepsy. 
Isojärvi et al. (1996) reported that PCO and/or hyperandrogenism were found in 64% of 
women using VPA compared to 19% in controls. These women had also a higher level of 
serum testosterone, dehydroepiandrosterone (DHEAS) and insulin levels and lower serum 
levels of sex-hormone binding globuline (SHBG). Accordingly, Rättyä et al. (2001) showed 
that after one month of VPA medication, the levels of testosterone, luteinizing hormone (LH) 
and follicle-stimulating hormone (FSH) increased. However, data in this area can be 
conflicting (Morrow and Craig 2003). Bauer et al. (2000) found no difference in the 
prevalence of PCOS in women using VPA or CBZ for epilepsy compared with untreated 
epileptic women.  
 
Obesity is also more common in women using VPA (59 %) and obesity-associated PCOS has 
been thought to have an important role as a source of the menstrual disturbances in women 
using VPA (Isojärvi et al. 1993 and 1996). In the study of Isojärvi et al. (1993), the effects of 
VPA were more common in women who had received the AED medication before the age of 
20. 
 
Epilepsy, epileptic seizures and AEDs may have an effect on the hormones involved in 
endocrine regulation (Morrel 1998; Herzog 2006). These include an increase in prolactin 
levels after tonic-clonic seizures and direct effects on the hypothalamic-pituitary axis e.g. 
altered secretion of gonadotrophins. Conversely, these hormones may have an effect on the 
seizures – generally it has been considered that estrogens are proconvulsants whereas 
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progesterone has anticonvulsant properties (Tettenborn et al. 2002). This has been associated 
with a specific type of epilepsy, catamenial epilepsy, in which the seizure frequency seems to 
vary according to the cyclical hormonal changes during the menstrual cycle (Tettenborn et al. 
2002).   
 
CBZ and other enzyme-inducing AEDs (e.g. phenytoin (PHT) and oxcarbazepine (OXC)) 
which induce hepatic microsomal enzymes of the P-450 system, can evoke interactions with 
endogenous and exogenous hormones (Zupanc 2006). These AEDs increase steroid 
metabolism and affect protein binding and therefore by accelerating the metabolism of ethinyl 
estradiol, reduce the effectiveness of hormonal contraception. CBZ has also been reported to 
increase the level of SHBG in women with epilepsy which decreases the free progestin levels 
in the plasma (Isojärvi et al. 1996; Rättyä et al. 2001). Therefore the risk of contraceptive 
failure and breakthrough bleeding in women with epilepsy using AEDs is more common than 
in the general population and this needs to be taken into consideration when treating women 
with epilepsy (Tomson 2004a; Zupanc 2006). 
 
The effects of epilepsy and AEDs on sexual functioning, have been studied in recent years. In 
these studies, women with epilepsy have reported sexual dysfunction more often than controls 
(Morrell et al. 2005). This is especially prevalent in women with localization related epilepsy 
(Morrell et al. 2005). In the study by Herzog et al. (2003), sexual dysfunction was more often 
present in women with TLE and especially right-sided TLE whereas no difference was found 
between women treated with and without AED treatment indicating an independent role of 
epilepsy in this respect. In terms of the specific AEDs, enzyme-inducers including PHT had a 
negative impact on sexual functioning (Morrel et al. 2005).  
 
2.7. Epilepsy and pregnancy   
 
2.7.1. Maternal outcome 
 
Though the majority of the women with epilepsy enjoy uncomplicated pregnancies (Tomson 
and Battino 2005), women with epilepsy have been reported to have a greater risk of 
pregnancy complications than control women (Yerby et al. 1985; Sabers et al. 1998; Pilo et al. 
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2006). Some of the most frequently reported complications include toxaemia, bleeding in 
pregnancy, placental abruption; both induced and prolonged labour and an increase in the rate 
of caesarean sections. However, conflicting data concerning the adverse effects of epilepsy 
and AEDs on pregnancy outcome have been published, and in many of the later studies very 
few differences have been noted between women with epilepsy and controls with respect to 
pregnancy complications (Hiilesmaa et al. 1985; Yerby 1991; Morrow et al. 2003). In a 
Finnish study of pregnant women with epilepsy in an outpatient clinic material, pregnancy 
complications occurred as frequently in women with epilepsy as in controls (Hiilesmaa et al. 
1985). In a recent study the rate of complications in pregnancy was increased only with 
respect to hypertension (not associated with pre-eclampsia) and induced delivery (Richmond 
et al. 2004).  
 
Pregnancy may also have an effect on epilepsy since it may cause a change in seizure 
frequency, a decline in serum AED levels and changes in AED pharmacokinetics. In a recent 
report by the EURAP Study Group (2006) 58% of the women were seizure-free during 
pregnancy and the seizure frequency was unchanged in 63 % of the women. An increase in 
the number of seizures was observed in 17% of the women and the occurrence of seizures was 
independently associated with AED polytherapy and localization-related epilepsy. A similar 
increase in seizure frequency has been observed independently in a Swedish (Tomson et al. 
1994) and an Italian study (Tanganelli and Regesta 1992), in which the increase in the seizure 
frequency was also associated with focal epilepsy and women with a higher frequency of 
seizures also in the pre-pregnancy period. In a review prepared by Tomson (1997a) it was 
noted that approximately 5% of women with epilepsy experience seizures during labour, 
delivery or immediately thereafter. Status epilepticus (SE) is of special concern at any time, 
but especially during pregnancy. However, SE does not occur more frequently during 
pregnancy and it is observed in less than one percent of pregnancies (Tomson 1997a).  
 
Pregnancy alters many of the mechanisms associated with the pharmacokinetics of the AEDs. 
The serum levels of AEDs tend to decrease, most likely due to decreased protein binding, 
changes in the blood volume or changes in drug metabolism (Tomson 2004a). In some 
patients this decline of AED levels may affect the seizure frequency during pregnancy. In the 
study of Yerby et al. (1992), the total concentrations of several AEDs (CBZ, PHT, PB, VPA) 
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declined significantly during pregnancy, but the free concentrations of the drugs remained 
unchanged or even increased (VPA). Accordingly, Tomson et al. (1994) reported that though 
total plasma levels of CBZ decline during pregnancy, the free plasma levels stay the same or 
even increase due to decreased protein binding. The same study showed no association 
between plasma AED levels and seizure control during pregnancy (Tomson et al. 1994). A 
pronounced increase in the clearance of lamotrigine (LTG) during pregnancy has been 
demonstrated (de Haan et al. 2004). The fall in LTG plasma levels during pregnancy is 
considerably greater than that reported for other AEDs, and could result in an increase in 
seizure frequency thus necessitating dose adjustment. The active monohydroxy derivative of 
oxcarbazepine (OXC), which is mainly responsible for the drug’s pharmacological effect, 
shares with LTG a primary route of elimination via glucuronidation and it seems to also 
undergo the same kind of pharmacokinetic alterations during pregnancy that are observed for 
LTG (Mazzucchelli et al. 2006).  
 
In some women, the increased seizure frequency may be due to lack of compliance during 
pregnancy, usually due to fear of the teratogenic effects of AEDs (Tanganelli and Regesta 
1992; Tomson 2004a). Although the absolute risk is low, maternal death has been estimated 
to be ten times higher for women with epilepsy than those in the general population (Adab et 
al. 2004b). Case histories suggest that these fatalities are a result of the seizures that are often 
associated with abrupt withdrawal of AEDs or with poor compliance. Also environmental 
factors e.g. sleep deprivation and anxiety during pregnancy, have been suggested as reasons 
for the increased seizure frequency. Adequate pre-pregnancy counseling is essential to 
increase the likelihood of maintained seizure control: a lack of such counseling has been 
identified as a major risk factor for an increase in seizure frequency during pregnancy (Lopes-
Cendes et al. 1992). 
 
2.7.2. Fetal outcome 
 
Some of the reported fetal complications associated with maternal epilepsy are spontaneous 
abortion, intrauterine growth retardation, asphyxia, low Apgar scores and increased perinatal 
mortality, but data are often conflicting and complication rates vary between different studies 
(Yerby et al. 1985; Sabers 1997). In the prospective, multicenter study of Battino et al. (1999) 
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the overall proportion of children with low birth weight was not increased. However, the 
Danish prospective, cohort study of Hvas et al. (2000) reported that children exposed to AEDs 
were small for gestational age (SGA) and they had reduced body length and head 
circumference compared with unexposed children. A low birth weight was also reported by 
Yerby et al. (1985) in a large, population-based retrospective study. In the Swedish 
prospective study of Wide et al. (2000) a slight decrease in body weight was observed in 
infants exposed to polytherapy, in particular the head circumference was reduced in infants 
exposed to CBZ. Battino et al. (1999) reported that a small head circumference was associated 
with polytherapy and the use of PB and primidone. This smaller head circumference in a 
combination therapy of PB and PTH has also been reported in a retrospective analysis of 
Dessens et al. (2000). In the Finnish population- based prospective study published by Gaily 
et al. (1990a), a reduction in the head circumference was shown in children exposed to CBZ 
and a combination therapy of barbiturates with the difference persisting for up to five years. 
However, the paternal head circumference was also below the average in these two groups 
and the difference in the children disappeared after adjusting for paternal head circumference 
(Gaily et al. 1990a). Thus genetics may contribute, at least partially, to the head 
circumference of the AED exposed children. Pilo et al. (2006) reported that children exposed 
to AEDs suffer a higher frequency of respiratory distress syndrome.  
 
Maternal seizures during pregnancy may have an adverse effect on the fetus. A decrease in 
fetal heart rate has been observed after maternal tonic-clonic seizures, and this has been 
considered to be due to changes in the blood circulation, transient lactic acidosis and asphyxia 
(Hiilesmaa et al. 1985). In addition, trauma caused by tonic-clonic seizure may harm the 
fetus. However, in the recent prospective study by Kaaja et al. (2003), maternal seizures 
during the first trimester were not associated with congenital malformations.  
 
It has been thought previously that infants exposed to enzyme-inducing AEDs in utero are at a 
risk of having complications due to neonatal bleeding. This may be due to a deficiency of 
vitamin K1 in the fetus induced by the AEDs. Therefore many guidelines have recommended 
vitamin K1 supplementation (American Academy of Neurology 1998; Morrow and Craig 
2003). However, in the first epidemiological study assessing the occurrence of bleeding 
complications in newborns, no difference was noted between controls and infants exposed to 
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AEDs (Kaaja et al. 2002). In a logistic regression analysis, the bleeding was associated with 
premature birth (<32 weeks) and alcohol abuse, but not to enzyme-inducing AEDs. Similarly, 
in another study from the United States, no haemorrhagic disease was observed in newborns 
exposed to AEDs (Choulika et al. 2004). 
 
Perinatal mortality has been observed to be two to three times higher in infants of mothers 
with epilepsy compared to controls (Sabers 1997). In the study of Hiilesmaa et al. (1985), the 
rate of perinatal deaths was 5/150 (three stillbirths and two deaths during the first week of 
life). However, in the report of Annegers et al. (1988) no association was found between 
maternal epilepsy and the use of AEDs with any recognized foetal loss. 
 
2.7.2.1  Major malformations 
 
The increased risk in the rate of major congenital malformations (MCM) in children of 
mothers with epilepsy is well established (Samrén et al. 1997; Wide et al. 2004; Wyszynski et 
al. 2005). It has been related to the use of AEDs, especially to AED polytherapy during 
pregnancy (Kaneko et al. 1999; Richmond et al. 2004). No increase in the rate of 
malformations has been observed in children of mothers with epilepsy but without AED 
medication (Holmes et al. 2001). Also the type of maternal epilepsy has not been associated 
with different rates of malformations (Kaneko et al. 1988). In some AED regimens, a dose-
dependent mechanism of teratogenesis has also been observed (Samrén et al. 1997).  
 
In the prospective, multicenter study by Kaneko et al. (1999) MCMs were observed in 9.0 % 
of the AED exposed children compared to 3.1% of those without drug exposure. Pooled risks 
for MCMs in children exposed to AEDs vary from two to fourfold in different studies (Dravet 
et al. 1992; Olafsson et al. 1998; Canger et al. 1999; Artama et al. 2005). With respect to the 
individual drugs, PB, primidone and VPA, have been reported to have the highest association 
with malformations according to Kaneko et al. (1999). In a recent prospective Finnish study, 
the rate of MCMs was 3.8% compared to 0.8% in control population and the risk was 
independently associated with the use of CBZ, VPA, OXC, low serum folate concentration 
and a low maternal level of education (Kaaja et al. 2003). 
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Of the currently used AEDs, VPA has most often been associated with a higher frequency of 
malformations than other AEDs (Samrén et al. 1997; Canger et al. 1999; Wide et al. 2004). 
This risk of MCMs was four-fold compared to other AEDs according to the North American 
pregnancy registry and over 7- fold to women without AEDs (Wyszynski et al. 2005). The 
risk of MCMs was increased in women receiving VPA at doses of >1000mg/day compared 
with women receiving VPA <600mg/day indicating a dose-dependent teratogenic effect 
(Samrén et al. 1997). This teratogenic effect at high VPA doses (>1100 mg/day) has also been 
reported in the preliminary data of the Australian Pregnancy Registry (Vajda et al. 2006). 
However, data from the UK Register suggest that even low doses of VPA may be no worse in 
this respect than >200 mg/day doses of lamotrigine (Morrow et al. 2006) and suggest a dose-
dependent effect of CBZ, LTG and VPA. A dose-dependent effect has been suggested also for 
PB in a retrospective analysis of birth register information (Samrén et al. 1999).  
 
In a meta-analysis of the teratogenicity of CBZ, the malformation rate was 6.8 % compared to 
2.34 % in controls in patients with CBZ monotherapy and this was increased up to 18.8% in 
polytherapy pregnancies (Matalon et al. 2002). This especially harmful effect of polytherapy 
has been reported in many studies (Kaneko et al. 1988; Holmes et al. 2001). In the 
prospective study of Kaneko et al. (1988), the frequency of MCMs was highest in the 
combination therapy of VPA and CBZ and/or PHT.  
 
Perucca (2005) summarized the information of the recent malformation studies. The results of 
the MCM rates have varied several-fold between different studies though this is partially due 
to study designs and methodological differences (Perucca 2005). However, many studies have 
suggested that exposure to VPA is associated with a greater incidence of MCMs than other 
AEDs, especially at doses above 1000 mg/day (Samrén et al. 1997; Kaneko et al. 1999; 
Artama et al. 2005).  The studies showed no consistent differences in the rate of MCMs 
between CBZ, PHT and PB. However, the difference in risk of MCM between VPA and CBZ 
was significant in three studies (Wide et al. 2004; Artama et al. 2005; Morrow et al. 2006). 
Figure 2 illustrates the results of five recent malformation studies and the MCM rates with 
different AEDs compared with CBZ. 
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Figure 2. Odds ratios and 95% confidence intervals for major congenital malformations 
associated with prenatal exposure to antiepileptic drugs in monotherapy, relative to the odds 
ratio for malformations with carbamazepine exposure (Modified from Perucca 2005).   
 
 
A variety of MCMs have been described in children exposed to AEDs e.g. spina bifida, cleft 
lip/palate, hypospadias, cardiac and circulatory malformations (e.g. persistent left superior 
vena cava), anomalies of the face and limb defects. In the international register study of 
Arpino et al. (2000), spina bifida was associated with VPA exposure (OR 5.7) but less often 
with CBZ exposure (OR 2.8). Neural tube defects were associated with the use of VPA and 
CBZ also in the study of Lindhout et al. (1992). PB was more commonly associated with 
cardiac (OR 2.2) and circulatory (OR 4.1) malformations (Arpino et al. 2000). In the meta-
analysis of CBZ teratogenicity, the most frequent malformations were cardiac and urinary 
tract anomalies (Matalon et al. 2002). 
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As emphasized previously, neural tube defects e.g. spina bifida have been observed more 
commonly in women using AEDs (especially VPA and CBZ) compared to reference 
populations. A reduction in the rate of neural tube defects was noted after administration of 
folic acid supplementation preconceptually in the general population (Wald and Sneddon 
1991). Also in normal pregnancies, without AEDs, the serum folate levels decline and in 
pregnant women with epilepsy the decline is even steeper (Dansky et al. 1992). Therefore, it 
has been recommended that women with epilepsy should receive adequate folic acid 
supplementation preconceptually until the end of the first trimester, though no clear 
association has been shown to support the belief that this strategy decreases the number of 
neural tube defects in infants of mothers with epilepsy (Morrow and Craig 2003; Tomson 
2004b). It has also been suggested that high-dose folic acid substitution may even be seizure-
provoking or may have an association with an increased risk of miscarriages but this 
information is still needing to be confirmed (Tomson 2004b). In a Swedish study reported by 
George et al. (2002), an association of low plasma folate levels and an increased risk of early 
spontaneous abortion was established but no association was found with high levels of folate.  
 
When one wishes to assess the risk of MCMs in the children of epileptic mothers, AEDs 
(dosages and combinations) are not the only contributing factors. Genetic factors may also 
play a role in malformations. Malm et al. (2002) published a case report in which three sets of 
siblings born to mothers with epilepsy and exposed to VPA in utero were examined. All of 
the children in these three families exhibited fetal valproate syndrome, which strongly 
suggests that there is a hereditary susceptibility to valproate. Also it is likely that 
pharmacogenetics has an impact on the teratogenicity of AEDs. Finnell et al. (1992) studied 
phenytoin-induced teratogenesis. During the metabolism of PHT, oxidative metabolites are 
produced e.g. epoxides. Those children exposed to PHT and who developed a fetal hydantoin 
syndrome had lower epoxide hydrolase levels than children with PHT exposure but without 
malformations, emphasizing that individual genetic factors may be involved in the 
teratogenicity e.g. determining the activity of specific enzymes.  
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2.7.2.2. Minor malformations and fetal anticonvulsant syndrome 
 
In addition to major malformations, minor malformations/anomalies (usually defined as 
unusual morphological features with no serious medical or cosmetic consequences to the 
patient) which become recognizable later in life have been found to be more common in AED 
exposed children (Yerby et al. 1992; Wide et al. 2000). In a prospective study by Koch et al. 
(1992) infants exposed to AEDs had a higher number of anomalies than children of mothers 
with epilepsy but without AED exposure (5.03 vs. 1.91). In children exposed to VPA, this 
value was even higher (8.0). However, children of fathers with epilepsy did not show more 
anomalies than control children (Koch et al. 1992). Also in a Swedish population-based 
prospective study, the number of minor anomalies was increased in children exposed to AEDs 
in utero, but the children had rarely more than one anomaly and no specific pattern of 
anomalies could be identified (Wide et al. 2000).  
 
In a large retrospective analysis of Adab et al. (2004a), dysmorphic features were observed in 
44 % of children exposed to VPA compared to 9% in children exposed to CBZ. Also in the 
retrospective study of Kini et al. (2006), children exposed to VPA exhibited a higher 
proportion of dysmorphic features compared with children exposed to CBZ and PHT. 
However, also 45% of the children with no AED exposure were found to have dysmorphic 
features indicating that single minor anomalies are common also in the general population 
(Kini et al. 2006). Dysmorphic features in AED exposed children have been associated with 
the cognitive outcome (Adab et al. 2004a; Holmes et al. 2005). In the studies of Adab et al. 
(2004a) and Kini et al. (2006), children with dysmorphic features and VPA exposure had 
lower VIQ scores than children without dysmorphic features.  
 
In a population-based prospective study by Gaily et al. (1988a), the minor anomalies in AED 
exposed children were studied. The anomalies were subdivided into typical anomalies 
(epicanthus, hypertelorism, typical nose, long philtrum, abnormal ears, low hairline, nail 
hypoplasia, distal phalangeal hypoplasia, and three or more dermal arches) and other 
anomalies; no excess of the other anomalies were observed in these children (Gaily et al. 
1988a). Some of the anomalies may also be genetically determined as they reported that also 
the mothers had more minor anomalies than control women. Of the many reported anomalies, 
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only the association between distal phalangeal hypoplasia and phenytoin has been well 
established (Gaily et al. 1990c).  
 
Fetal anticonvulsant syndrome (FACS) term is often used when referring to children who 
have suffered adverse teratogenic effects due to AED exposure. FACS refers to a group of 
disorders in which malformations and developmental disorders occur in association with a 
characteristic facial appearance. Characteristic dysmorphic features as well as malformations 
have been described in children exposed to PHT, VPA and CBZ. However, the extent of 
developmental problems in these children is less known.  
 
The term of fetal hydantoin syndrome was first introduced by Hanson and Smith (1975). It 
consisted of typical minor anomalies (e.g. epicanthus, hypertelorism and long philtrum) and 
included also mental deficiency, growth retardation and microcephaly. Also specific facial 
features have been associated with VPA exposure and a fetal valproate syndrome was 
described in 1984 by DiLiberti et al. In the retrospective cohort study of Kini et al. (2006), a 
large variety of dysmorphic features was recognized both in AED exposed children as well as 
in control children indicating that some of the typical FACS features are common also in the 
general population. However, features noted more often in valproate exposed children were 
medial deficiency of eyebrows, infraorbital grooves, broad nasal bridge, anteverted nose, 
abnormal philtrum and a thin upper lip (Kini et al. 2006). In CBZ exposed children, full 
cheeks with a small chin and an everted lower lip were more common (Kini et al. 2006). 
Moore et al. (2000) studied 57 children with FACS who were identified through the FACS 
Association and found that 33% of the exposed children had glue ear and up to 70% had a 
type of joint laxity. He also reported a similar facial dysmorphology in the exposed children 
as that described by Kini et al. (2006) though significant overlapping does seem to occur 
between different exposure groups and facial features. The study also reported a high 
frequency of autistic type behaviours and hyperactivity in children with FACS (Moore et al. 
2000). Kini et al. (2006) reported also a correlation between valproate exposure, dysmorphic 
features and low verbal IQ in children with FACS. However, prospective population based 
studies have not revealed similar results. In the study of Gaily et al. (1988b), the majority of 
the AED exposed children were exposed to PHT, and no children with typical fetal hydantoin 
syndrome features could be identified.  
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Abnormal ophthalmologic findings have been reported to be more common in children with 
FACS (Glover et al. 2002). Of the 46 children with FACS 67% had ocular abnormalities, 
most commonly errors of refraction (41%). In particular myopia (50%) was common in VPA 
exposed children. 
 
2.7.3. Cognitive and behavioural outcome 
 
After the studies were published describing the immediate teratogenic effects of AEDs, the 
question of the long term effects of AED exposure in utero, was raised. The first systematic 
studies concerning the long term cognitive effects of AED exposure were conducted in the 
1970´s and 1980´s. The prospective study by Gaily et al. (1988b) concluded that the children 
of mothers with epilepsy, most of whom had been exposed to AEDs in utero, had a lower 
mean intelligence quotient (IQ) than control children. Mental deficiency was observed in 
1.4% of the children and borderline intelligence in 1.7% of the children (Gaily et al. 1988b). 
Overall, however, the prevalence of mental deficiency was the same or slightly increased in 
children of epileptic mothers compared with unexposed children (Gaily et al. 1988b). Koch al 
al. (1999) reported the results of a longitudinal prospective study. They also found that the 
intelligence scores were lower in AED exposed children. This deficit was associated mainly 
with polytherapy with primidone but the socio-economic status of the family also had an 
effect on the cognitive outcome of the children (Koch et al. 1999).  
 
The effects of specific AED regimens have also been studied. In the prospective, population-
based study of Gaily et al. (1988b) the majority of the children were exposed to PHT (103 
children), which was also the case in the cohort study of Scolnik et al. (1994) (34 children). 
Gaily et al. (1988) found no association between low IQ and phenytoin exposure. Also the 
occurrence of brief maternal convulsions during pregnancy did not affect the cognitive 
outcome. In the smaller, prospective cohort study of Scolnik et al. (1994), children exposed to 
PHT had a lower global IQ as well as lower language developmental scores than unexposed 
controls. In the prospective, population-based study from Sweden, preschool-aged children 
with PHT exposure received lower scores in their locomotor development than control 
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children (Wide et al. 2004) although the number of children in PHT exposure group was 
rather small (N=15). 
 
In addition to PHT, the effects of CBZ exposure on the cognitive development of the children 
have been studied. Gaily et al. (2004) reported the results of a large population-based 
prospective study of the cognitive development of CBZ exposed children at preschool- and 
school-age. Children with CBZ exposure did not differ from controls and they were reported 
to have normal intelligence. This normal intelligence in CBZ exposed children has also been 
reported in other studies (Gaily et al. 1988b; Scolnik et al. 1994). Wide et al. (2000) studied 
the AED exposed children at the age of 9 months and at that time point no difference was 
noted in the development of the AED exposed children (of which the majority had been 
exposed to CBZ) compared with unexposed controls.  At preschool age the neurodevelopment 
of the CBZ exposed children was also reported to be normal (Wide et al. 2004). 
 
During recent years, interest has mainly been focussed on the effects of prenatal VPA 
exposure on the cognitive development of the exposed children. In particular exposure to 
VPA was associated especially with a lower VIQ compared with other monotherapy 
exposures in the prospective study of Gaily et al. (2004) and also in the retrospective study of 
Adab et al. (2004a). A negative correlation of the VPA dose and VIQ was observed, but 
neither the type of maternal epilepsy nor the occurrence of generalized seizures during 
pregnancy, were associated with this deficiency (Gaily et al. 2004). Also in children exposed 
to VPA, even though the individual variation in performance has been great, a large 
proportion of these children have been reported to exhibit an especially low IQ (Adab et al. 
2004a).  
 
An increased risk of poorer cognitive performance has been observed in children exposed to 
polytherapy compared to monotherapy exposure (Koch et al. 1999; Gaily et al. 2004; Adab et 
al. 2004a). In the study of Koch et al. (1999), both the PIQ and the VIQ were lower in 
children exposed to polytherapy but in addition to AEDs, the socio-economic status of the 
family was also predictive of the cognitive outcome. 
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In addition to the effect of AEDs, many confounding factors affect the cognitive outcome of 
the children. Predictive factors for the low VIQ in children exposed to VPA were maternal IQ 
and frequent tonic-clonic seizures (Adab et al. 2004a). According to Gaily et al. (1990b) 
several factors were associated with the cognitive dysfunction observed in children exposed to 
AEDs, i.e. maternal seizures during pregnancy, partial seizures and paternal level of 
education. In the study of Holmes et al. (2005), a lower IQ was observed in children with 
AED exposure and microcephaly compared to children with AED exposure but normal head 
circumference. The IQ deficit was also more commonly seen in children with midface 
hypoplasia. The socio-economic status of the family has also been reported to affect the 
cognitive outcome of the children (Koch et al. 1999). 
 
The cognitive and behavioural problems observed in children exposed to AEDs have been 
thought to lead to problems at school. Though the majority of the children with AED 
exposure attend mainstream school, a need for educational support and special arrangements 
regarding schooling have been reported (Adab et al. 2001). This reported risk has been 
especially prevalent in children with VPA exposure (Adab et al. 2001 and 2004a).  Autism 
and related disorders as well as behavioural problems are also more common in children with 
AED exposure (VPA, CBZ and polytherapy) than in unexposed children (Dean et al. 2002). 
In the population-based, retrospective study from UK, disorders of the autistic spectrum or 
Asperger syndrome were diagnosed in 4.6 % (12/260) of the AED exposed children (Rasalam 
et al. 2005). These disorders were most common among VPA exposed children 8.9% (5/56). 
Dessens et al. (2000) found that adults who had been exposed to PB and PHT in utero 
exhibited more learning problems and mental retardation than controls. However, in this area, 
no true prospective, population-based studies have been conducted. The studies of Adab et al. 
(2001 and 2004a), Dean (2002) and Rasalam (2005) had a retrospective design and in the 
study of Dessens et al. (2000) the recruitment of subjects was retrospective with a subsequent 
prospective follow-up. These methodological shortcomings may have biased the reliability of 
the results.  
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2.8. Pregnancy management, recommendations and birth registers 
 
Many guidelines have been given concerning the management of fertile-aged women with 
epilepsy. These recommendations have attempted to highlight the special concerns and 
provide answers to practitioners (ACOB 1997; Morrell 1998; Crawford 1999). The need of 
adequate pre-conception counselling for women with epilepsy is evident and emphasized also 
in the guidelines (Morrell 1998; Tomson 2004b). However, a prospective population based 
study analyzing the care of women with epilepsy reported that only 38% of the women had 
received pre-conceptional counselling and less than 50% of the women had planned their 
pregnancies (Fairgrieve et al. 2000). Therefore much work still needs to be done in order to 
optimize the treatment of women with epilepsy.   
 
In order to enable rational decisions, women with epilepsy and their partners need to be 
counselled about conception, pregnancy, breast-feeding and caring for the infant. The 
avoidance of unplanned pregnancy requires the use of effective contraception.  During 
counselling before conception, it is important to confirm the diagnosis of active epilepsy and 
reconsider the need for AED treatment (Kälviäinen and Tomson 2006). A woman who wishes 
to become pregnant and who has been seizure-free for two or more years may attempt to 
discontinue AEDs under supervision by her physician. The decision to withdraw medication 
gradually should follow the generally accepted principles for the treatment of adults with 
epilepsy. It will depend mainly on the level of risk that the individual patient is willing to 
accept. The risks include worsening of seizures, perhaps seizures that result in physical harm 
to the mother (and the fetus once the woman becomes pregnant). Although the risks are low, 
the possibility of status epilepticus and SUDEP should be discussed realistically before 
attempting drug withdrawal (Morrow and Craig 2003). If treatment is continued, the woman 
should use the most effective AED for her epilepsy type at the lowest possible dose to control 
seizures following the general principles for the treatment of epilepsy. The classification of 
the seizure and epilepsy syndrome should be re-evaluated and the appropriate medication 
adjusted accordingly (Kälviäinen and Tomson 2006).  
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The re-evaluation should be performed carefully for all patients, including those with 
difficult-to-treat epilepsies, to assess the possibility of improved seizure control with fewer 
AEDs. It is clear that some patients will still need polytherapy, but this should be limited to as 
few AEDs as possible. Epilepsy surgery may be an option in selected cases, e.g. in temporal 
lobe epilepsy, and this may eventually result in seizure control without drugs before the 
patient becomes pregnant (Kälviäinen and Tomson 2006). The treatment of new-onset 
epilepsy during pregnancy should follow the same principles as used in the non-pregnant 
woman.  
 
Low folate concentrations within maternal erythrocytes have been correlated with neural tube 
defects in infants (anencephaly, spina bifida, and encephalocele) (Fishman 2000). Therefore, 
it has been recommended that women with epilepsy should have a daily intake of 0.4mg of 
folate from the time they commence trying to become pregnant until the twelfth gestational 
week (Tomson et al. 1997b). If the woman has previously given birth to a child with a neural 
tube defect, the recommended daily folate supplement is 4 mg for the above-mentioned period 
(Tomson et al. 1997b). Many guidelines recommend higher doses of folate (4-5mg/day) also 
for women being treated with valproate or carbamazepine (AAN guidelines 1998). However, 
in this population, the documentation for any benefit of high-dose folate supplementation is 
lacking and unknown adverse events of high-dose folate supplementation cannot be excluded. 
In Finland, therefore, 1 mg supplementation has been used, which is also convenient for 
patients, as they only have to take one tablet per day and because the duration of 
supplementation may last for as long as several years in some patients. 
 
Ideally, drug levels should be obtained before pregnancy for comparison with the 
concentrations to be monitored during gestation. For highly protein bound AEDs, such as 
VPA and PHT, unbound levels are preferred. Drug level monitoring is most important for 
AEDs that may undergo major alterations in their active concentrations, e.g. PHT and in 
particular LTG, and for AEDs with unknown effects of pregnancy. Whether a decline in drug 
concentrations per se should prompt dosage adjustments is still controversial, but this kind of 
strategy appears to be justified, at least for LTG (Kälviäinen and Tomson 2006). Otherwise 
dose adjustments are made according to the level of seizure control.  
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All women with epilepsy who become pregnant should be referred to a specialist maternity 
unit and at least structural ultrasound should be performed. Most women will have a normal 
uncomplicated vaginal delivery, however, tonic-clonic seizures may result in fetal hypoxia. 
Therefore it is generally recommended that delivery takes place in a unit equipped with 
facilities for both maternal and neonatal resuscitation (Morrow and Craig 2003).  
 
AED levels quickly revert to pre-pregnancy levels after the delivery. Hence, if the dose of an 
AED has been increased during pregnancy because of falling AED-levels or seizures during 
pregnancy, it may be useful to measure plasma levels at 2-4 weeks after the delivery and 
make any necessary dosage adjustments. All women with epilepsy should be encouraged to 
breastfeed their babies (Crawford 1999; Morrow and Craig 2003). The AED concentration 
profiled in breast milk follows the plasma concentration curve. The total amount of drug 
transferred to infants via breast milk is usually much smaller than the amount transferred via 
the placenta during pregnancy.  
 
In Kuopio University Hospital, maternity and epilepsy clinics are jointly following up all 
women with epilepsy during their pregnancy with a pre-decided protocol (Table 2).   
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Table 2. Current follow-up protocol for pregnant women with epilepsy in the Kuopio 
University Hospital area (Kälviäinen 2004). 
 
Pre-conceptional 
counselling 
• Counselling for contraception until pregnancy is desired 
• Seizure-free patients - Discussing the possibility to 
withdraw AED treatment considering the risks 
• Most patients - Optimizing AED treatment according to 
seizure type and syndrome and counselling about 
teratogenicity 
• Prescription of folic acid before conception (1mg/day) 
until the end of 12th gestational week 
Pregnancy 
 
 
1st trimester (~ week 11) 
 
 
 
 
 
 
2nd trimester (~ week 19) 
 
 
 
 
3rd trimester (~ week 27) 
          
 
                      
 
after week 36  
Visit both to epilepsy and maternity clinics (preferably on the 
same day) 
 
Information to the mother about pregnancy, delivery and breast-
feeding 
Seizure control and AED medication, motivation for treatment 
Laboratory test – liver enzymes, blood count, AED plasma level 
measurements 
Ultrasound of the fetus (maternity clinic or personal physician) 
 
Structural ultrasound of the fetus in the maternity clinic 
Seizure control and AED treatment 
Risks of AED treatment to the fetus 
Laboratory test (if needed) 
 
Seizure control, AED treatment 
Laboratory test (if needed) 
Follow-up ultra-sound and examination in the maternity clinic 
 
 
Follow-up in the neurological clinic if needed 
Obstetric follow-up continues individually 
After delivery If seizure free during pregnancy – control visit 9-12 months after 
delivery 
 
If AED dosages change during pregnancy – adjustments of the 
AEDs according to plasma levels and clinical symptoms 2-4 
weeks after delivery 
 
Review of AED treatment and contraception 
Encourage preconceptional care for future pregnancies 
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Optimal AED treatment is essential not only during pregnancy in view of the recognized 
adverse effects of AEDs but also the threat of seizures, if left untreated. The need for 
information on the effects of the older and newer AEDs is essential. To achieve this purpose 
many international birth registries have been established to gather details of the effects of 
AEDs (Beghi et al. 2001). Current registries include for example EURAP, the UK Epilepsy 
and Pregnancy Register, Australian Pregnancy Registry and North American Antiepileptic 
Drug Pregnancy Registry (Holmes et al. 2004; Russel et al. 2004; Tomson et al. 2004c; Vajda 
et al. 2004). In the majority of these registries, information has been gathered prospectively, 
which hopefully will provide a source of unbiased information on the adverse effects of AED 
treatment and will help to improve the future treatment of women with epilepsy.  
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3. AIMS OF THE STUDY 
 
 
3.1. To determine the proportion of WWAE having children and to investigate factors related 
to fertility in women using VPA and CBZ 
 
3.2. To compare the course of pregnancy, delivery and pregnancy outcome in WWAE and in 
the general pregnant population 
 
3.3. To evaluate the possible effect of vigabatrin (VGB) treatment in utero to the visual 
function in the offspring 
 
3.4. To investigate the cognitive performance of school-aged children exposed to VPA in 
utero compared to children exposed to CBZ as well as to children without AED exposure 
 
3.5. To assess the neurological development, behavioural aspects and additional educational 
needs in children exposed to VPA in utero compared to children exposed to CBZ as well as to 
children without AED exposure. 
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4. SUBJECTS AND METHODS 
 
4.1. Subjects 
 
4.1.1. Study I 
 
All pregnancies in the Kuopio University Hospital (KUH) area (population 250 000) since 
1989 have been prospectively registered in the Birth Register of the Department of Obstetrics 
and Gynaecology. The term pregnancy is used when the gestational age is over 22 weeks or 
the birth weight over 500 gr. From this register, we retrieved all women who had a diagnosis 
of epilepsy in the data of the pregnancy registry and had been residents in the KUH area. Our 
study period was from January 1989 to October 2000 and during this period of time a total of 
85 women with active epilepsy (WWAE, women who had epilepsy and had used AED 
medication during conception and throughout the pregnancy) had a singleton pregnancy (127 
pregnancies) and 38 women who had a history of epilepsy but needed no AED medication 
during pregnancy (52 pregnancies). At the same time, 16505 women without epilepsy (24778 
pregnancies) had given birth. In the study group of 85 WWAE, 20 subjects had used VPA 
monotherapy during their pregnancy and 49 had received CBZ monotherapy. When multiple 
pregnancies were included, the numbers were 87 WWAE and 18146 control women.  
 
During same time period (1989-2000), 130 fertile-aged (18-40 years) women who had used 
VPA monotherapy and 316 women who had used CBZ monotherapy and were residents of 
the KUH area had visited the outpatient clinic of the Department of Neurology. To assess the 
fertility aspect more thoroughly, we reviewed the medical records of these 130 women with 
VPA monotherapy and selected 130 women with closest birth date and CBZ monotherapy as 
controls.  
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4.1.2. Study II 
 
In study II we examined the pregnancy outcome of the 85 WWAE compared to the outcome 
of the 38 women with a history of epilepsy but without AEDs and also compared these to the 
general population. The WWAE had given birth to 127 children and the other 38 women to 
52 children. Multiple pregnancies and major chromosomal anomalies were excluded from the 
pregnancy outcome analysis. As a control group we used all the pregnant women who had 
been registered to the Birth Register but who did not have epilepsy and had a singleton 
pregnancy (16505 women and 24778 pregnancies). See Figure 3 for study populations.  
 
 
 
Figure 3. Study populations  
 
 
 
Birth Register:  
(1989-10/2000) 
 
24957 pregnancies 
Singleton 
pregnancies of 
WWAE  
N = 127 
Pregnancies in 
women with a 
history of epilepsy 
N = 52 
Unaffected 
control 
pregnancies  
N = 24778 
Children with 
VPA exposure 
N = 28 
Children with 
CBZ exposure 
N = 72 
School-aged and 
first-born children 
with informed 
consent N = 13 
Controls with 
same age and 
gender N = 13 
Controls with 
same age and 
gender N = 13 Studies 
IV-V 
Study 
II 
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4.1.3. Study III 
 
From the Birth Register we were able to identify three women who had used VGB during 
pregnancy and four children who had been exposed to the drug. Of the four children exposed, 
we were able to examine two at school age to search for possible structural malformations and 
visual dysfunction. 
 
4.1.4. Studies IV-V 
 
All women who had epilepsy and had used VPA monotherapy during pregnancy were 
identified from the Birth Register. To investigate the effect of VPA exposure on the children, 
we examined the children at school age (≥ 6 years old). Out of the 28 VPA exposed children, 
16 were school-aged and first born during the study year (2003). Thirteen children 
participated in this controlled study, and also their mothers were examined. The controls were 
selected from the Birth Register children with the closest birth date and the same gender as 
the VPA exposed children. Thirteen control children were exposed to CBZ and 13 children 
had no AED exposure, but their mothers had a history of epilepsy.  
 
4.2. Methods 
 
4.2.1. Kuopio University Hospital Birth Register and register data used for fertility 
assessment (Studies I-II)          
 
The Kuopio University Hospital Birth Register contains comprehensive information regarding 
the background of the mother, risk factors, course of the pregnancy and pregnancy outcome. 
This information has been gathered to the register by questionnaires, which are sent to every 
mother during their pregnancy. These questionnaires are returned to the maternity clinic of 
KUH before the delivery and supplemented with information from the follow-up of the 
pregnancy, delivery and pregnancy outcome at the delivery unit of KUH. From this register, 
we obtained demographic data of the mothers and the information about the management and 
course of the pregnancy as well as the data of the outcome of the pregnancy. Also the medical 
records of the WWAE were reviewed and Birth Register information was supplemented with 
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the neurological data retrieved from medical records (e.g. the type of epilepsy, onset of 
epilepsy, frequency of seizures, AED medication). The WWAE had been followed up 
according to the pre-decided protocol (Table 2) jointly by the epilepsy and maternity clinics in 
KUH.   
 
To assess the overall fertility among women with epilepsy, we reviewed the medical records 
of our Neurology outpatient clinic between years 1989 and 2000. We reviewed the medical 
records of the 130 women with VPA monotherapy and of 130 women with CBZ monotherapy 
with the closest birth date. From the medical records, we obtained information concerning the 
number of children, hormonal disturbances (if any noted) and co-morbidities. We also looked 
for any available reasons for not having children. No structured interview for the women was 
used.  
 
In addition to information obtained from the Birth Register and medical records of the women 
studied, we retrieved epidemiological information from the Statistics Finland and from 
STAKES (National Research and Development Centre for Welfare and Health). According to 
Statistics Finland, 23% of Finnish women did not have children in the year 2000. To confirm 
the number of women having active epilepsy and using AED medication in KUH area, we 
assessed information obtained from the Social Insurance Institution of Finland (KELA). 
Overall, 286 women (16-39 years) in KUH area had active epilepsy in year 2000. The registry 
of STAKES provided information of fertile-aged women (16-39 years) (N = 36261) living in 
the same hospital area at the same time (in the year 2000).  
 
Premature delivery was defined as delivery before gestational week 37, and prolonged 
pregnancy as lasting longer than week 42. Small-for-gestational-age newborns were below the 
tenth percentile according to the normal tables of our population when adjusted for the 
gestational age and sex. Infants with birth weight less than 2500g were considered to have 
low birth weight. Fetal distress term was used when fetal venous pH was <7.15 and/or Apgar 
scores at 5 minutes were <7 after birth. Major malformations were defined as structural 
abnormalities with surgical, medical or cosmetic importance identified by a pediatrician at 
birth and at discharge from hospital.  
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4.2.2. Assessment of the AED exposed children 
 
4.2.2.1 Study III 
 
The medical records of the mother and children exposed to VGB were reviewed with respect 
to medication, seizures and neonatal information. A paediatric neurologist performed a 
thorough examination of the children and an ophthalmologist examined both the mothers and 
the children for any visual dysfunction. Visual acuity as well as visual fields were examined. 
A standard ophthalmologic evaluation was performed to exclude other eye diseases. The 
ophthalmologic examination consisted of a history of visual symptoms, testing the best 
corrected visual acuity, phorias and tropias, biomicroscopy, and indirect ophthalmoscopy with 
the aid of tropicamide 0.8% + phenylephrine 5% drops. Intraocular tension was measured 
with the Goldmann applanation tonometer. Visual fields were examined with the kinetic 
Goldmann perimeter.  
 
 
4.2.2.2 Studies IV-V 
 
The 13 children exposed to VPA in utero and their age- and gender matched controls were 
examined and interviewed in the facilities of Clinical Research Center of Kuopio University. 
They were first examined by a pediatric neurologist and then underwent a detailed evaluation 
of neuropsychological functioning supervised by a psychologist lasting for 2 hours. Both the 
pediatric neurologist and psychologist were blinded to the medical history and the drug 
exposure of the children and mothers. The medical records of the children and their mothers 
were reviewed and all relevant information concerning e.g. pregnancy and delivery, the type 
of epilepsy and the use of AEDs and/or other medications, seizures before and during the 
pregnancy, the pre-, peri- and postnatal details of growth and possible problems in 
neurological development of the child were all recorded. The medical information was 
combined with the information from the Birth Register and with the data from the clinical and 
neuropsychological examinations.  
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4.2.2.2.1 Neurological evaluation 
 
The neurological functioning of the children was assessed by using Touwen’s test (Touwen 
1979). This standardized examination was used to detect any possible minor neurological 
dysfunctions of the child and to exclude other neurological diseases that could influence the 
results of the cognitive and neuropsychological evaluation. The results of the examination in 
Touwen’s test are represented in six subsystems: sensorimotor function, posture, balance, 
physical coordination, fine-finger dexterity and dyskinesia. Mild neurological dysfunction is 
determined to be present if there are deficits in one or two of the categories and severe 
(neurological impairment) if deficits are seen in over two categories. Minor dysmorphic 
features were evaluated during the neurological evaluation from a checklist for dysmorphic 
features and the results were based on blinded, but individual, non-controlled clinical 
evaluation by a paediatric neurologist. Dysmorphic features were defined as unusual 
morphological features with no medical importance of cosmetic consequence to the patient. 
We individually sought facial anomalies (epicanthal folds, hypertelorism, flat nasal bridge, 
long philtrum, midface hypoplasia, cleft lip or palate and other noted abnormalities of the 
face) and abnormalities of the hand (finger and nail hypoplasia). Other observed anomalies 
e.g. of the skin and joints, were also recorded if noted. 
 
4.2.2.2.2 Neuropsychological evaluation 
 
The general cognitive function of all mothers was evaluated with the Wechsler Adult 
Intelligence Scale (WAIS, Wechsler 1955) or WAIS- Revised (Wechsler 1981). Full scale 
intelligence Quotient (FIQ), verbal IQ (VIQ) and performance IQ (PIQ) were estimated on the 
basis of six subtests: Information, Similarities, Digit Span, Digit Symbol, Picture Completion 
and Block Design. 
 
The children underwent individual neuropsychological assessments using the Wechsler 
Intelligence Scale for Children III (WISC-III; Wechsler 1991) and the NEPSY, a 
Developmental Neuropsychological Assessment (Korkman, Kirk and Kemp, 1998). Scores 
for FIQ, for VIQ and for PIQ were estimated in the same way as WAIS. Low intelligence was 
determined to be present if the FIQ score was less than 80 and exceptionally low intelligence 
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if the score was <70. Eight subtests of the NEPSY evaluating five cognitive domains were 
administered: the Tower from Attention and Executive functions; Comprehension of 
Instructions and Verbal Fluency from the Language domain; Visuomotor Precision from the 
Sensorimotor domain, and Arrows from the Visuospatial domain. In addition, from the 
Memory and Learning subtests, Memory for Faces, Narrative Memory and List Learning 
were administered. 
 
4.2.2.2.3 Behavioural assessment  
 
The Conners’ Teacher Rating Scale – questionnaire (CTRS) was sent to every family and 
after it was completed by teachers it was sent back for a further analysis of the behavior of the 
child. The rating scale consists of (56) individual questions scored from zero (definitely not) 
to three (definitely true). These individual questions were further categorized into 13 different 
domains according to the Conners’ manual. These categories are Oppositional, Cognitive 
Problems/Inattention, Hyperactivity, Anxious-Shy, Perfectionism, Social Problems, Conners’ 
ADHD Index, Conners’ Global Index: Restless-Impulsive, Conners’ Global Index: Total, 
DSM-IV: Inattentive, DSM-IV: Hyperactive-Impulsive and DSM-IV: Total. The raw scores 
of the rating scale were then transformed into standard points, which permitted a comparison 
between children of different ages and sexes. 
 
4.2.3. Statistical analysis 
 
The SPSS statistical package (Ver. 9.0-13.0) was used for statistical analysis. In all of the 
studies, t-test was used for normally distributed continuous variables and chi-square for 
dichotomous variables. Fischer’s exact test was applied when the expected count was less 
than five. Confidence intervals of 95% were used and P-values <0.05 were considered as 
being statistically significant. Multiple logistic regression analysis, BMDP, was used to 
evaluate the effect of maternal risk factors on the pregnancy outcome in Study II. The 
pregnancy outcome variables were adjusted for all significant or nearly significant maternal 
risk factors (p<0.1). In study IV for the comparison of the cognitive level of mother-child 
pairs, the IQs were classified into categories of cognitive ability levels according to standard 
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deviation units above and below the mean. In studies IV-V, Kruskall-Wallis test was used for 
continuous variables.  
 
4.2.4. Ethics 
  
This study was approved by the ethics committee of the Kuopio University Hospital and 
Kuopio University. Informed consent was obtained in study III-V from the mothers and those 
children who could understand the meaning of consent.  
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5. RESULTS 
 
5.1. Epilepsy and female fertility (Study I) 
 
The average number of children in WWAE was 2.1 ± 1.3 and in healthy pregnant population 
2.2 ± 1.2 (p=0.6, NS). In KUH area, 4.7 per 1000 pregnancies (0.47%) involved a mother 
with active epilepsy. At the same time, 0.79 percent of the fertile-aged population in KUH 
area had active epilepsy and according to these numbers (0.47/0.79) 60% of women with 
active epilepsy had given birth to a child. In Finland, 77 % of women have children according 
to Statistics Finland (2005).  
 
The menstruation cycle was regular in 85 % of controls and in 83 % of WWAE. No 
difference was noted in the time needed to become pregnant between WWAE and controls 
(4.7 months vs. 5.4 months, median 2 months in both groups). Overall 7.6 % of the control 
women had used some form of fertility treatment, in WWAE, the equivalent figure was 4.7% 
(NS) and none of the women in valproate group had used treatment for infertility.  
 
Of the 118 women with VPA monotherapy attending the neurology outpatient clinic, 61 
women (52 %) had given birth to a child with the respective figures for those with CBZ 
medication being 66 and 58 %.  Figure 4 shows the stated reasons for not having children for 
WWAE with the most frequently used monotherapies (data for CBZ and VPA patients 
combined). No significant differences were noted between women using VPA and CBZ in the 
studied variables. 
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Women with epilepsy and reasons for not having children
56 %
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Death
No reason available from the
medical records  
Figure 4. Women with active epilepsy with monotherapy on either carbamazepine or 
valproate, and stated reasons for not having children. 
 
 
5.2. Epilepsy and pregnancy (Study II) 
 
Women with active epilepsy gave birth at the age of 29 ± 5 years as did the controls. 
Monotherapy was in use in most pregnancies (104/127, 82%), duotherapy in 20 cases (16 %) 
and polytherapy with 3 drugs in 3 cases (2%). In the majority of the pregnancies, CBZ 
(72/127) 57% and VPA (28/127) 22% monotherapies were in use. Adequate folic acid 
substitution was used in 26 pregnancies (20%).  
 
The seizure type was partial with and without secondary generalization in most patients 
(68%) and generalized (e.g. absence or myoclonic seizures) in 14% of cases, and the exact 
type of seizures could not be determined in a minority of the (15%) cases. 
 
The majority of the mothers were seizure-free during the pregnancy (80/127, 63%) and 
47/127 (37%) experienced seizures during pregnancy. In all, 56% of the patients did not 
experience any change in their seizure frequency and 27% had encountered a change for 
better (83% no change or change for better). A change for the worse in seizure control 
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occurred in 18% of the pregnancies but no specific reason, which could explain this 
exacerbation of seizures, was found. One woman had a status epilepticus (SE) during both her 
pregnancies and another woman experienced a flurry of seizures and a cesarean section was 
performed during the premonitory phase of SE. 
 
The study populations were similar with regard to the maternal risk factors and pregnancy 
complications. There were no statistically significant difference in the duration of the 
pregnancy in WWAE 280 ± 14 days, in women with non-active epilepsy 280 ± 13 days and in 
the control group 278 ± 16 days.  
 
The odds ratios for selected pregnancy outcome variables between study groups are presented 
in Figure 5. A significant number of the children of WWAE were found to be small for 
gestational age (SGA), but no differences were found in the number of newborns with low 
birth weight. No difference was noted in the AED medication or seizure frequency during 
pregnancy in the mothers of SGA children. However, the mothers with SGA children seemed 
to be shorter than mothers without SGA children (161.4 ± 6.4 cm vs. 164.9 ± 5.7 cm, p<0.05). 
Apgar scores at 1 minute in children of WWAE were low, but no longer at the age of 5 
minutes. Accordingly, the admissions for neonatal intensive unit or to neonatal ward were 
significantly (p=0.01) more prevalent in children of WWAE (N=17, OR 1.98, 95% CI 1.17-
3.34).  
 
In the VPA group, 11/20 (55%) deliveries were induced compared to 16.7 % of the control 
women, p<0.0001. The CBZ group did not differ from controls in this respect. Identified 
reasons for the induction were postmaturity (3 pregnancies), pre-eclampsia (2), abnormal fetal 
cardiotocography (2), absent or uncoordinated contractions (2) and social reasons (2).  
 
The frequency of major malformations was 4.8% (95% CI -0.6-10.2) in the children of 
WWAE, while no major malformations were found in the children of women with a history of 
epilepsy but who were not using AEDs during pregnancy. The malformations are described in 
detail in study II. All children with the malformations had been exposed to polytherapy or 
high-dose monotherapy with VPA or CBZ. 
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Figure 5. Pregnancy outcome variables of women with active epilepsy (adjusted for maternal 
age >35 years, pregravid body mass index >25kg/m2 and unemployment of the mother).   
(FHR = fetal heart rate, CI = confidence interval, OR = odds ratio) 
 
 
5.3. Children and mothers exposed to vigabatrin (Study III) 
 
There were two mothers who had used polytherapy (CBZ and CBZ + VPA) with VGB during 
pregnancy. The total dose of VGB in the first mother 190g was during the pregnancy and 
370g in the second mother. In the two exposed children, no ophthalmologic structural 
abnormalities were detected. Visual field testing was unreliable and therefore visual 
dysfunction could not be assessed. 
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5.4. Neurological assessment of the exposed children at school-age (Studies IV-V) 
 
In the standardized neurological evaluation of the Touwen’s test, neurological dysfunction 
was found in 8/39 (20.5%) of the studied children (5 VPA, 1 CBZ and 2 no AED). Two of the 
VPA exposed children had autistic and regressive behavioral features which were suggestive 
of low intelligence and three had developmental verbal dysfunction and one of them had also 
difficulties in tasks related to co-ordination of extremities and fine motor functions. The one 
CBZ exposed child had learning difficulties. In the group of no AED exposure, one child had 
delayed development of expressive speech and the other exhibited dysfunction in fine motor, 
balance and co-ordination.  
 
Both the need of additional educational support in school and the need for rehabilitation (e.g. 
speech therapy) were increased in children exposed to VPA compared to either those with 
CBZ exposure or those with no AED group. In all, 5/8 (63%) of the children in VPA group 
needing additional educational support had subnormal intelligence whereas the other 3/8 
(37%) had average intelligence. A summary of the neurological findings of the children are 
described in Table 3. 
 
Table 3. Summary of the neurological findings of the AED exposed children at school-age. 
 
 
NI = neurological impairment, FIQ = full intelligence quotient, SD = standard deviation, 
Minor dysmorphology ≥ 1 minor anomalies 
 
 Touwen’s test  
 
N (%) 
Minor 
dysmorphology 
N (%) 
FIQ  
 
N (%) 
 
Rehabilitation  
 
N (%) 
Educational 
support 
N (%) 
 normal  NI + - normal <1 SD 
 
<2 SD + - + - 
VPA 8(62) 
 
5(38) 
 
8(62) 5(38) 8(62) 3(23) 2(15) 4(32) 9(69) 8(62) 5(38) 
CBZ 12(92) 1(8) 3(23) 10(77) 11(85) 2(15) 0 0 13(100) 2(15) 11(85) 
No 
AED 
11(85) 2(15) 3(23) 10(77) 13(100) 0 0 1(8) 12(92) 2(15) 11(85) 
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5.5. Neuropsychological assessment of the exposed children (Studies IV-V) 
 
In the neuropsychological evaluation of the children, all children with no AED exposure and 
almost all of the children exposed to CBZ could perform adequately in the subtest of NEPSY 
and scored within one S.D. from the mean. Two to four children of the VPA group could not 
perform all of the NEPSY subtests. Those children who could perform adequately scored 
statistically significantly lower in the subtest of Memory for Faces (p= 0.016 compared to 
CBZ) and in the List Learning subtest (p= 0.008 compared to no AED exposure group). The 
scores of the neuropsychological tests are reported in study IV. 
 
Table 4 shows the results of the WISC scores in children and WAIS scores of the mothers. 
Mothers with VPA had a significantly lower IQ and educational level than women using CBZ 
and women without AED exposure. Also children exposed to VPA had a trend towards lower 
IQ scores than the other children, though this difference did not reach statistical significance. 
Also in the different WISC subtests, the VPA exposed children scored lower than the other 
children. Two of the children with VPA exposure had exceptionally low intelligence 
(FIQ<80) while their mothers had average intelligence. Children with CBZ exposure did not 
differ from controls and had normal intelligence. Also the mothers using CBZ had IQ scores 
similar to controls. The values of the WISC subtest scores are reported in detail in study IV.  
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Table 4. Intelligence quotients of the mothers and children not exposed to antiepileptic drugs 
(No AED), exposed to carbamazepine (CBZ monotherapy) and exposed to valproate (VPA 
monotherapy) and level of education (years) in mothers 
 
AED groups No AED 
 
(N=13) 
CBZ 
monotherapy 
(N=13) 
 
VPA 
monotherapy 
(N=13) 
All 
 
( N = 39) 
p-values 
WAIS IQs, education 
Mean maternal FIQ (95% CI) 
Mean maternal VIQ (95% CI) 
Mean maternal PIQ (95% CI) 
Maternal education  years 
(S.D.) 
 
AED exposure groups 
 
WISC-III IQs 
Mean FIQ children (95% CI) 
Mean VIQ children (95% CI) 
Mean PIQ children (95% CI) 
 
 
108.8 (105.0-112.5) 
107.5 (101.3-113.8) 
109.5 (105.1-113.9) 
14.2 (2.3) 
 
 
No AED (N=13) 
 
 
99.6 (95.0-104.3) 
98.2 (91.2 -105.2) 
102.1 (94.1-110.0) 
 
 
109.2 (102.0-116.4) 
105.1 (96.8-113.4) 
112.5 (105.1-119.9) 
14.8 (2.2) 
 
 
CBZ (N = 13) 
 
 
98.9 (91.2-106.5) 
96.5 (86.9-106.0) 
102.5 (93.7-11.4) 
 
95.6* (89.5-101.8) 
92.9* (85.8-100.1) 
99.5* (92.4-106.7) 
12.5* (1.9) 
 
 
VPA (N = 13) 
 
 
84.5 (69.4-99.7) 
85.1 (70.2-99.9) 
84.7 (68.4-101.0) 
 
104.5 (100.8-108.2) 
101.1 (97.5-106.2) 
107.2 (103.3-111.0) 
13.8 (2.3) 
 
 
All ( N = 39) 
 
 
94.3 (88.6-100.1) 
93.7 (87.2-99.3) 
96.4 (89.8-103.1) 
 
0.003** 
0.012* 
0.022* 
0.035* 
 
 
p-values 
 
 
0.157 NS 
0.269 NS 
0.071 NS 
 
5.6. Behavioural assessment (Study V) 
 
Conners’ Teacher Rating Scale was used to detect possible behavioural problems in these 
school-aged children. Children exposed to VPA received generally higher scores in all of the 
analysed domains but due to small number of patients, these differences did not reach 
statistical significance. However, in two of the categories (social problems, p=0.07 and 
cognitive problems/inattention, p=0.09) the VPA-exposed children showed a tendency 
towards more behavioural problems. Children with CBZ and no AED exposure had very 
similar scores and no statistical differences were noted between these two groups.  
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5.7. Dysmorphic features and the overall neurocognitive development 
 
Dysmorphic features were seen in 8 children (62%) exposed to VPA and in three children 
(23%) in both the CBZ and the no exposure group (p = 0.085). Four of the thirteen VPA 
exposed children (31%) had 2 or more of these features. All the children in CBZ group had 
only one minor dysmorphic feature and one child in the no exposure group had two features. 
If the AED exposed children were summed together (VPA + CBZ) 11/26 (42 %) had 
dysmorphic features compared to 23 % (3/13) in children with no AED exposure. The most 
frequently observed features were flat nasal bridge, long philtrum and thin upper lip, 
epicanthal folds and short fingers.  
 
The overall performance of the AED exposed children was evaluated to obtain a 
comprehensive view of their neurodevelopment. The results of the Touwen’s test, FIQ, 
dysmorphic features, additional educational support, need for therapies and Conners’ Global 
Index scores were grouped together. If all of the results fell in the normal range, the children 
were categorized as having normal neurodevelopment, minor dysfunction if performance in 
one or two of the categories was abnormal and as neurologically impaired if problems were 
seen in more than two categories. All of the children exposed to VPA had minor or major 
neurological/cognitive problems. The majority of the children exposed to CBZ and without 
AED exposure had normal performance or only minor problems. 
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6. DISCUSSION 
 
This study consists of five individual scientific papers which focus on (1) the fertility of 
WWAE in the area of Kuopio University Hospital and the effects of co-morbidities and AEDs 
on fertility, (2) the management and outcome of the pregnancies of WWAE, (3) the effect of 
VGB exposure on visual function, (4) the long-term cognitive and (5) behavioral development 
of the AED exposed children. Information of WWAE was obtained from the Birth Register of 
KUH and from the records of the Neurology Outpatient Clinic covering the hospital district 
providing a population-based, comprehensive data of the pregnancies. This prospective, 
population-based study of the AED exposed children has provided valuable information for 
the monitoring of the cognitive effects of AEDs.  
 
6.1. Fertility 
 
In our population, 60% of women with epilepsy had children compared to 77 % of unaffected 
women. We believe that the most important factor explaining this 22% difference is the 
higher number of co-morbidities (mental retardation and psychiatric disorders) observed in 
women with epilepsy; they accounted for 15 to 18 percent in our study in monotherapy 
population with well-controlled epilepsy and up to 29 % in the study of Forsgren (1992). In 
our study, approximately 20% of women did not have any recognized or reported reason for 
not having children. This number was identified from the medical records and therefore may 
include a bias in that the women may not have told the physician the real reason for not 
having children. However, we believe that this bias is not significant because these women 
were mainly seen in our hospital at regular intervals and any infertility problems would be 
treated mainly at KUH. Also the proportion of women not having children is fairly close to 
that found in the general population (23% of women not having children) when the influence 
of co-morbidities is excluded.  
 
The majority of the studies concerning fertility in women with epilepsy have reported a 
decreased fertility (Webber et al. 1986; Wallace et al. 1998). In these studies however, the 
higher prevalence of severe co-morbidities in women with epilepsy compared to controls was 
not taken into consideration. Severe co-morbidities e.g. mental retardation will independently 
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affect the patient’s social environment and her possibility to have children. In the population-
based study by Olafsson et al. (1998b), the fertility rate was the same in women with epilepsy 
and controls and the fertility was reduced only in women with epilepsy together with a severe 
co-morbidity e.g. cerebral palsy or mental retardation. These co-morbidity rates have been 
studied by Forsgren (1992) showing that in both women and men with epilepsy, the 
percentage of coexisting diseases/disabilities is as high as 47%, with contribution of mental 
retardation being 23% and severe psychiatric condition being 6%.  
 
Our findings are in concordance with the results of Olafsson et al. (1998b) and the research of 
Artama et al. (2004) where the fertility rate in women with epilepsy was 0.88 of the reference 
population. In addition, we found no difference in the time needed to become pregnant or in 
the need for fertility treatments between WWAE and controls. No significant changes were 
observed in the regularity of menstrual cycles, in the marriage rate or in the mean number of 
infants. Also, no significant differences were noted between women using VPA those using 
CBZ in terms of fertility or menstrual disturbances. Tettenborn et al. (2002) also concluded 
that there are misconceptions in relation to fertility in women with epilepsy and that these 
women do not have markedly reduced fertility compared to controls. 
 
6.2. Pregnancy outcome 
 
In our carefully monitored population with its pre-decided follow-up protocol, no significant 
differences were found between WWAE and controls in the frequently reported pregnancy 
complications. This result was consistent with the prospective results of Hiilesmaa et al. 
(1985) and with the recent obstetric study of Richmond et al. (2004). However, the rate of 
small for gestational age (SGA) infants was significantly higher in WWAE than in the 
reference group, as was also observed in the prospective study by Hvas et al. (2000). This 
increase in the number of small-for-date infants could not be explained by preterm delivery or 
low birth weight because their number was not increased. Furthermore, neither the epilepsy 
type nor the AED medication differed between mothers with SGA children and those giving 
birth to normal weight infants. Also no increase was noted in the number of SGA children in 
mothers with epilepsy but without AED medication. The mothers with SGA children, 
however, were shorter which partially could have contributed to the outcome.  
 63
 
Apgar scores at 1 minute after birth were lower in infants of WWAE but no longer reduced at 
the age of 5 minutes and accordingly the need of neonatal care after birth was increased when 
compared to controls. Over half (55%) of the deliveries of women using VPA had to be 
induced. This need for induced delivery has been observed before in women with epilepsy but 
not associated so clearly with women using VPA (Yerby et al. 1985). There were many 
different reasons for induction; no dominating reason could be identified. This finding needs 
to be confirmed in further studies.  
 
The overall rate of major malformations is 4.8% in our study. The malformations were 
identified by a pediatrician at birth and at discharge from hospital. No reference group 
examined with a similar method for identifying malformations was available. However, 
according to information from STAKES, the mean malformation rate is 2.9% (1993-2000) 
among all newborns, indicating an approximately two-fold increase in the rate of 
malformations seen here, which is in concordance with previous studies (Olafsson et al. 1998; 
Canger et al. 1999; Artama et al. 2005). The malformations occurred in children exposed to 
either polytherapy or high-dose monotherapy (either CBZ or VPA) and were similar to those 
reported in literature. No association between specific AEDs and malformations could be 
drawn from this material. In previous prospective studies, the higher rate of malformations 
has also been associated with polytherapy or high-dose monotherapy, especially with VPA 
(Kaneko et al. 1988; Wide et al. 2004).  
 
These findings underline the importance of careful pregnancy monitoring in WWAE. 
Furthermore, the deliveries should take place in a hospital equipped and prepared for neonatal 
intensive care. 
 
6.3. Ophthalmologic findings of the offspring exposed to vigabatrin 
 
In our case-report of the effects of AED polytherapy with VGB, no structural abnormalities 
were found in the two VGB exposed children. However, visual fields could not be measured 
reliably and no conclusions of the possible visual dysfunction can be drawn. It is, however, 
well established that patients using VGB are at an increased risk of having bilateral, absolute 
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concentric constriction of the visual field, with varying degrees of severity (Kälviäinen and 
Nousiainen 2001). Also in the first, controlled and systematic evaluation of the ocular 
outcome in children exposed to AEDs during pregnancy, no serious defects were associated 
with AED exposure (Fahnehjelm et al. 1999). However, none of the children in the study of 
Fahnehjelm et al. (1999) had been exposed to VGB and therefore it is important to gather 
information from the possible adverse effects also from these case-report studies.  
 
6.4. Neurodevelopmental outcome and dysmorphic features 
 
We evaluated the neurodevelopment of AED exposed children in a prospective, population-
based study. Only a few studies with prospective and population-based design have been 
conducted previously (Gaily et al. 1988; Wide et al. 2002). In the VPA exposed children, the 
scores of FIQ, VIQ and PIQ were lower than in other groups, though due to the small group 
size, the difference did not reach statistical significance. In the VPA group the prevalence of 
low intelligence (FIQ <80) was 38% and exceptionally low (FIQ <70) intelligence was 
detected in 15% of the children. In previous population-based studies, VPA exposed children 
have been reported to have lower VIQ than control children (Gaily et al. 2004). This specific 
influence on verbal performance was not observed in our study. In the retrospective study of 
Adab et al. (2004a), the lower VIQ in VPA exposed children was independently associated 
with maternal IQ, VPA exposure and five or more tonic-clonic seizures during pregnancy. In 
our study, the mothers using valproate scored significantly lower than women with CBZ and 
those without AED medication in FIQ, VIQ and PIQ tests, though most of the results fell 
within the normal range. Also their level of education, measured in years, was significantly 
lower than that of the controls. However, only one mother in each group experienced tonic-
clonic seizures during pregnancy and each had only one seizure. Therefore it is evident that 
many confounding factors can influence the cognitive outcome of the AED exposed children. 
In our study, the lower level of schooling and cognitive performance of the mothers using 
VPA could have contributed to the unfavourable neurocognitive outcome of their children. 
Also in the study of Gaily et al. (2004), the mothers of children with VPA exposure had had 
lower maternal education. 
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In the study by Gaily et al. (2004), a negative trend of VPA dose and VIQ score was found. 
Adab et al. (2004a) reported also a dose-dependent relationship of VPA and VIQ – children 
exposed to VPA doses >800mg/day during the first trimester had lower VIQ but no 
relationship was found in doses <800mg/day. In our study, the average dose of VPA was 
1182 mg/day and the women with CBZ medication were taking 751mg /day. Due to the small 
sample size, no association could be detected between the VPA dose and possible cognitive 
effects derived from this drug. 
 
The children with CBZ exposure did not differ from control children and had average 
intelligence. This finding is in agreement with the previous population-based studies (Gaily et 
al. 2004; Wide et al. 2004), in which normal intelligence has been observed in children 
prenatally exposed to CBZ. 
 
The scores of the IQ tests of the mothers and the children cannot be compared directly as the 
tests used are different (WAIS and WISC, respectively) and the tests have been standardized 
for different kinds of populations and age-groups. The mean FIQ scores were higher in 
mothers (WAIS) compared with the FIQ scores of WISC in children, reflecting perhaps this 
difference between the IQ tests. 
 
When assessing the AED exposed children at school age, 42% exhibited dysmorphic features; 
this value rose to 62% if only children exposed to VPA were taken into account. These 
children had one or more dysmorphic features. These have been associated with intelligence 
scores in the retrospective study of Adab et al. (2004a). In our study, 14% (2/14) of children 
with dysmorphic features had also subnormal intelligence. However, single dysmorphic 
features are common also in the general population (Kini et al. 2006) and therefore the 
significance of these features in AED exposed children needs to be interpreted cautiously. In 
this respect, our numbers are similar to those reported by Wide et al. (2000).  
 
Eight (62%) children with VPA exposure and 15 % of children with CBZ or those without 
AED exposure needed additional educational support. The need was clearly increased in VPA 
exposed children compared to that in general Finnish population (appr. 18%) (Michelsson and 
Stenman 2001). This is in concordance with the results of Adab et al. (2001). These findings 
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indicate that the cognitive problems observed in these children in the neuropsychological test 
have clinical significance and accordingly, their need for educational support is elevated. No 
other prospective population-based studies examining the need for additional educational 
support have been reported. 
 
Children exposed to VPA scored also higher than the other children in Conners’ Teacher 
Rating Scale indicating behavioural problems, although this difference did not reach statistical 
significance. The high scores seem to focus on areas of social problems and cognitive 
problems/inattention. The increased need of special education reported by Adab et al. (2001) 
could reflect this increase in behavioural problems. The possible behavioural problems in 
AED exposed children, is a field which has rarely been studied since it is difficult to study 
objectively and it has a susceptibility to bias. These findings are preliminary and need to be 
confirmed in further prospective, large-scale studies.  
 
When the performance of each child studied at school-age was analysed, it showed that all of 
the children exposed to VPA had at least minor and some of them exhibited major 
neurological or cognitive problems. This finding is of special concern. Although the study 
population is small, it is population-based, prospective and comprehensive. However, many 
significant confounding factors, e.g. genetic traits, environmental variables, control of 
mothers; epilepsy after delivery, and parenting habits and abilities are very difficult to control 
in this kind of study setting and probably have also influenced the outcome. 
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7. CONCLUSIONS 
 
1. There is no significant difference between the fertility rates in WWAE and the general 
population when severe co-morbid factors are excluded. Clinically relevant hormonal 
disturbances or treatments for fertility problems did not seem to be more common in 
WWAE compared with controls. 
 
2. The majority of women with epilepsy enjoy uncomplicated pregnancies and good 
obstetric outcome, when a pre-decided protocol is used for both obstetrical and 
neurological follow-up in antenatal care. However, the increased number of small for 
gestational age infants as well as the need for neonatal intensive care underline the 
importance of careful pregnancy and delivery monitoring. Major congenital 
malformations were observed in 4.8 % of the pregnancies.  
 
3. In the ophthalmologic examination, no structural abnormalities were found in the two 
children exposed to VGB in utero.  
 
4. Though many confounding factors influence the cognitive outcome of the AED exposed 
children, an unfavourable impact of VPA exposure on cognition cannot be excluded. 
However, children exposed to CBZ do seem to have normal intelligence. 
 
5. All of the children exposed to VPA had at least minor and some of them suffered from 
major neurological or cognitive problems. The frequency of behavioural problems and the 
need for additional educational support were increased in VPA exposed children. 
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